SB 001 - AcadeMab Biomedical
Alternative Names: hAbs SB-01; SB-001 - AcadeMab BiomedicalLatest Information Update: 12 Dec 2022
At a glance
- Originator AcadeMab Biomedical
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 30 Nov 2022 Early research in COVID-2019 infections in Taiwan (Parenteral) before November 2022 (AcadeMab Biomedical website, November 2022)
- 08 Aug 2022 AcadeMab intends to obtain emergency use authorization in COVID-2019 infections in USA
- 08 Aug 2022 AcadeMab plans a phase I trial in COVID-2019 infections in June 2023